Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Published Time:
2024-10-23 17:49
Source:
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
Following its inclusion in the 2022 list, Jiangsu Vcare's reappearance in 2024 reflects the industry's full recognition of its innovation strength. Since inception, Jiangsu Vcare has prioritized innovation as its core driver, continuously advancing technological transformation. In recent years, the company has significantly increased R&D investment, recruited top talent, and procured internationally advanced equipment, demonstrating unwavering commitment to innovation.
Jiangsu Vcare has established cutting-edge technology platforms—including AI molecular generation, drug screening, crystal/salt form selection, and novel formulations—focusing precisely on therapeutic areas such as cardiovascular, oncology, inflammation, and autoimmune diseases. Currently, it has5 clinical-stage Class I innovative drug projectsand over10 preclinical projectsunder development, forming a diversified, high-potential R&D pipeline.
Moving forward, Jiangsu Vcare will adhere to its innovation-driven and globalized strategy, targeting frontier technologies and unmet clinical needs to develop breakthrough therapeutics, contributing "Vcare Power" to global health.
Related News
08
2024
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) reported positive results from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the treatment of ankylosing spondylitis (AS).
View Details
02
2024
/
07
Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
View Details
07
2024
/
06
Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
View Details
28
2024
/
04
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of participants enrollment in its Phase I clinical trial for VC005, a second-generation selective JAK1 inhibitor developed as a topical gel formulation for the treatment of mild-to-moderate atopic dermatitis (AD). The trial included four cohorts of healthy volunteers and three cohorts of patients. The blinded analysis demonstrated promising efficacy and safety profiles for the drug.
View Details
20
2024
/
03
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of moderate-to-severe atopic dermatitis (AD). Preliminary blinded analysis from the clinical trial demonstrated promising efficacy and safety profiles for VC005.
View Details
07
2024
/
02
I. Important Progress in Innovative Drug R&D ① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke. ② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months. ③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety. Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn